Bristol-Myers Squibb stock jumps on schizophrenia drug approval

Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia drug.

Previous post Chinese stocks could surge higher as investors get ‘FOMO,’ Goldman Sachs says
Next post Treasury yields edge lower ahead of PCE inflation report